MyFinsight
Home
Blog
About
Contact
Download
Download image
Comprehensive loss
-$23,585K
(46.26%↑ Y/Y)
Net loss
-$23,574K
(46.23%↑ Y/Y)
Unrealized loss on
investments
-$11K
(73.81%↑ Y/Y)
Income tax benefit
(expense)
-$4,772K
(-1317.35%↓ Y/Y)
Zusduri
$29,246K
Jelmyto
$21,713K
Loss before income
taxes
-$28,346K
(34.76%↑ Y/Y)
Interest and other
income, net
$608K
(-71.24%↓ Y/Y)
Revenue
$50,959K
(151.60%↑ Y/Y)
Operating loss
-$20,263K
(45.11%↑ Y/Y)
Financing on prepaid
forward obligation
$4,506K
(-1.68%↓ Y/Y)
Interest expense on
long-term debt
$4,185K
(2.88%↑ Y/Y)
Gross profit
$46,820K
(161.21%↑ Y/Y)
Cost of revenue
$4,139K
(77.64%↑ Y/Y)
Selling, general and
administrative expenses
$51,486K
(47.24%↑ Y/Y)
Research and development
expenses
$15,597K
(-21.51%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd. (URGN)